Cardonilizumab

DRUG3 trials

Sponsors

Shanghai Zhongshan Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Tongji Hospital

Conditions

Biliary Tract CancerCandonilimabChemoradiotherapyClaudin 18.2Esophageal CancerEsophageal Squamous Cell CarcinomaImmunotherapyInduction Therapy

Phase 1

Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Active, not recruitingNCT05994001

Shanghai Zhongshan HospitalBiliary Tract Cancer, Candonilimab, Claudin 18.2

Start: 2023-08-01End: 2026-12-01Updated: 2026-02-18

Phase 2

Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

RecruitingNCT06421376

Cancer Institute and Hospital, Chinese Academy of Medical SciencesChemoradiotherapy, Esophageal Cancer, Immunotherapy +2

Start: 2024-05-01End: 2027-12-31Target: 60Updated: 2025-05-30

Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma

RecruitingNCT07699185

Tongji HospitalEsophageal Squamous Cell Carcinoma

Start: 2024-01-29End: 2026-07-01Target: 336Updated: 2026-07-13

Related Papers

Two stage, multi-center trial of cadonilimab and LM-302 for patients with CLDN18.2+ biliary tract cancer (BTC) that failed chemotherapy and PD-(L)1 antibody (ZSAB-Calm).

Journal of Clinical Oncology2024-06-013 citations